AXIM Biotechnologies, Inc.
Cash Flow Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.1M | $-6.2M | $-16.0M | $-6.4M | $-6.4M | $-6.8M | $-4.2M | $-5.8M |
| Depreciation & Amortization | $427.0K | $426.1K | $2.1M | $16.0K | — | — | — | $3.4K |
| Depreciation | $32.6K | $31.7K | $27.8K | $16.0K | $3.4K | $3.4K | $3.4K | $3.4K |
| Amortization | $394.4K | $394.4K | $2.1M | $0 | $3.2K | $9.5K | $0 | — |
| Stock-Based Compensation | $197.7K | $1.1M | $1.1M | $2.3M | $1.8M | $911.3K | $55.8K | $1.4M |
| Net Cash from Operating Activities | $-1.0M | $-2.0M | $-2.5M | $-3.2M | $-5.0M | $-4.8M | $-3.1M | $-1.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $8.7K | $40.5K | $97.3K | — | — | — | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-8.7K | $-50.5K | $10.0K | $348.2K | $0 | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.1M | $1.6M | $2.5M | $3.2M | $3.4M | $4.6M | $4.4M | $1.9M |
| Net Change in Cash | — | — | $-4.2K | $-54.4K | $-1.3M | $-252.2K | $1.3M | $579.2K |
| Free Cash Flow | $-1.0M | $-2.1M | $-2.5M | $-3.3M | — | — | — | $-1.3M |